Table 2.
Baseline characteristics of patients (n = 207) after PSM.
| ETV Group | TDF Group | p-Value | |
|---|---|---|---|
| (n = 130) | (n = 77) | ||
| Age (years) | 53 (46.25, 64) | 54 (46, 62) | 0.856 |
| Gender | 0.276 | ||
| women | 18 (14) | 6 (8) | |
| men | 112 (86) | 71 (92) | |
| Diabetes (N, %) | 0.434 | ||
| absence | 118 (91) | 73 (95) | |
| presence | 12 (9) | 4 (5) | |
| Hypertension (N, %) | 0.302 | ||
| absence | 113 (87) | 62 (81) | |
| presence | 17 (13) | 15 (19) | |
| Complications (N, %) | 1 | ||
| absence | 130 (100) | 77 (100) | |
| Cirrhosis (N, %) | 1 | ||
| absence | 20 (15) | 12 (16) | |
| presence | 175 (87) | 75 (74) | |
| Tumor size (cm) | 2.2 (1.7, 2.8) | 2.2 (1.7, 2.6) | 0.819 |
| Tumor number (N, %) | 0.095 | ||
| 1 | 121 (93) | 76 (99) | |
| 2 | 9 (7) | 1 (1) | |
| Platelet (×103/mm3) | 150 (108.5, 195) | 157 (112, 195) | 0.952 |
| PT (s) | 12.1 (11.53, 12.7) | 12.1 (11.6, 12.7) | 0.708 |
| APTT (s) | 28.1 (25.67, 30.63) | 27.6 (25.4, 30.2) | 0.477 |
| Albumin (g/dL) | 42.96 ± 3.67 | 43.73 ± 4.34 | 0.171 |
| Total bilirubin (mg/dL) | 14.85 (10.7, 20.07) | 13.3 (11.1, 18.1) | 0.342 |
| ALT (U/L) | 32.5 (22.22, 42.08) | 34.2 (21.5, 44.2) | 0.5 |
| AST (U/L) | 28.75 (23.23, 37.15) | 32.7 (24.7, 39) | 0.199 |
| Log10HBV DNA (IU/mL) | 0 (0, 4.22) | 2.08 (0, 4.7) | 0.161 |
| AFP (ng/mL) | 13.37 (3.98, 158.88) | 15.52 (4.85, 120.1) | 0.884 |
| AFP (ng/mL) | 0.533 | ||
| <20 | 73 (56) | 39 (51) | |
| ≥20 | 57 (44) | 38 (49) | |
| Child–Pugh class (N, %) | 0.305 | ||
| A | 198 (98) | 102 (100) | |
| B | 4 (2) | 0 (0) | |
| ALBI (N, %) | 0.715 | ||
| Grade 1 | 107 (82) | 61 (79) | |
| Grade 2 | 23 (18) | 16 (21) |
Categorical variables are described as frequencies and percentages. Continuous variables are described as mean ± standard deviation (SD) and median with interquartile range for parametric and nonparametric variables, respectively.